User login
Click here to read the supplement.
EXECUTIVE SUMMARY
With the many advances and introduction of new therapies for treating people with hemophilia A, this paper posits an illustrative model for assessing the value proposition of selected factor VIII (FVIII) replacement concentrates. Five marketed recombinant FVIII (rFVIII) products are compared across 4 major areas of hemophilia management: prophylaxis (preventive treatment), breakthrough bleed resolution, on-demand treatment, and inhibitor management. The 5-product landscape is set in a hypothetical health plan with 525 hemophilia A patients. Analysis inputs included are product dose, dosing frequencies, average bleed rates, product price, and high-titer inhibitor development rates. After comparing and contrasting the 5 selected rFVIII replacement concentrates across the 4 major areas, we concluded that cost-avoidance modeling in hemophilia A is worthwhile, possible, and particularly helpful in assessing the value proposition of rFVIII therapies. In our evaluation, we observed that NUWIQ® is a cost-effective rFVIII therapy for treating hemophilia A patients.
Click here to read the supplement.
Click here to read the supplement.
EXECUTIVE SUMMARY
With the many advances and introduction of new therapies for treating people with hemophilia A, this paper posits an illustrative model for assessing the value proposition of selected factor VIII (FVIII) replacement concentrates. Five marketed recombinant FVIII (rFVIII) products are compared across 4 major areas of hemophilia management: prophylaxis (preventive treatment), breakthrough bleed resolution, on-demand treatment, and inhibitor management. The 5-product landscape is set in a hypothetical health plan with 525 hemophilia A patients. Analysis inputs included are product dose, dosing frequencies, average bleed rates, product price, and high-titer inhibitor development rates. After comparing and contrasting the 5 selected rFVIII replacement concentrates across the 4 major areas, we concluded that cost-avoidance modeling in hemophilia A is worthwhile, possible, and particularly helpful in assessing the value proposition of rFVIII therapies. In our evaluation, we observed that NUWIQ® is a cost-effective rFVIII therapy for treating hemophilia A patients.
Click here to read the supplement.
Click here to read the supplement.
EXECUTIVE SUMMARY
With the many advances and introduction of new therapies for treating people with hemophilia A, this paper posits an illustrative model for assessing the value proposition of selected factor VIII (FVIII) replacement concentrates. Five marketed recombinant FVIII (rFVIII) products are compared across 4 major areas of hemophilia management: prophylaxis (preventive treatment), breakthrough bleed resolution, on-demand treatment, and inhibitor management. The 5-product landscape is set in a hypothetical health plan with 525 hemophilia A patients. Analysis inputs included are product dose, dosing frequencies, average bleed rates, product price, and high-titer inhibitor development rates. After comparing and contrasting the 5 selected rFVIII replacement concentrates across the 4 major areas, we concluded that cost-avoidance modeling in hemophilia A is worthwhile, possible, and particularly helpful in assessing the value proposition of rFVIII therapies. In our evaluation, we observed that NUWIQ® is a cost-effective rFVIII therapy for treating hemophilia A patients.
